Atorvastatin price trends in different countries
Pro Research Analysisby 
Searched over 200M research papers
Atorvastatin Price Trends: International Comparisons
Atorvastatin Price Variation Across Countries
Atorvastatin prices show significant variation across different countries, influenced by national policies, market dynamics, and regulatory frameworks. For example, before generic atorvastatin entered the market, New Zealand had the lowest price per defined daily dose (DDD) at $0.10, while the Republic of Korea had the highest at $2.89. After generics became available, all countries except New Zealand saw immediate price drops, with Singapore experiencing the largest initial decrease of 46%. Four years after generic entry, prices had fallen by 46–80% in Australia, New Zealand, the Republic of Korea, and Singapore, but substantial price differences remained between these countries.
Impact of Pricing Policies and Regulations
Countries with tendering systems and preferred medicine policies, like New Zealand, achieved the lowest atorvastatin prices both before and after generic entry. In contrast, Australia’s combination of mandatory price cuts and price-disclosure policies led to similar relative price reductions as tendering systems. The Republic of Korea, which relied solely on mandatory price cuts, saw the smallest relative reduction after four years. In Greece, strict pricing regulations set generic atorvastatin prices at 65% of the reference off-patent price, resulting in prices up to 52.73% lower than in other EU countries with the lowest originator prices. Additional rebates and clawbacks further reduced Greek prices by about 30%.
Price Trends in Europe and Australia
In Belgium, the introduction of generic atorvastatin led to projected price reductions of 50–70%, resulting in significant annual savings for the healthcare system. Atorvastatin was expected to become the dominant statin, with a market share of up to 66% by 201578. In Norway, generic competition and prescribing restrictions led to a 55% decrease in statin expenditure between 2004 and 2009, despite increased utilization. In Australia, even after a 25% voluntary price cut, atorvastatin remained much more expensive than in New Zealand, where patients paid less than A$2 per month. The price differential highlighted the need for further reforms in Australia’s pharmaceutical pricing policies.
Atorvastatin Price Variation Within Countries
In India, there is a huge price variation among different brands of atorvastatin. Studies found that the costliest brand of atorvastatin 40mg could be more than four times the price of the cheapest brand, with a price variation of up to 1592.85% for the 10mg dose. This wide disparity places a significant financial burden on patients and underscores the importance of careful prescribing and regulatory oversight345.
Cost-Effectiveness and Market Impact
The availability of generic atorvastatin has generally improved cost-effectiveness compared to other statins like simvastatin, especially at higher doses. In Belgium and other European countries, generic atorvastatin was found to be cost-effective and projected to generate substantial savings for healthcare payers78. However, in some countries, simvastatin remained less expensive than atorvastatin, even after generic entry.
Conclusion
Atorvastatin prices vary widely across and within countries, shaped by national pricing policies, market competition, and regulatory strategies. Countries employing tendering systems and strong price regulation, such as New Zealand and Greece, achieve the lowest prices. In contrast, countries with less aggressive policies or greater brand competition, like India and Australia, experience higher prices or greater price variation. The introduction of generics consistently leads to significant price reductions, but the extent of these reductions depends on the specific policy environment in each country.
Sources and full results
Most relevant research papers on this topic